Literature DB >> 20399897

Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review.

J Martel-Pelletier1, S Kwan Tat, J-P Pelletier.   

Abstract

OBJECTIVE: Osteoarthritis is a chronic disease characterized by irreversible damage to joint structures, including loss of articular cartilage, inflammation of the synovial membrane, and alterations in the subchondral bone. Symptomatic slow-acting drugs for osteoarthritis have been proposed as treatment because of their excellent safety profile. This review summarizes some data relating to the mechanisms of action of chondroitin sulfate in the pathophysiology of osteoarthritic joint tissues.
METHODS: Peer-reviewed articles obtained using pre-defined search criteria and published in the PubMed database are summarized. In addition, a relevant in press paper is included.
RESULTS: Chondroitin sulfate belongs to the group of glycosaminoglycans and is a major component of articular cartilage. The effect of chondroitin sulfate in patients with osteoarthritis is possibly the result of the stimulation of the synthesis of proteoglycans and the decrease in catabolic activity of chondrocytes by inhibiting the synthesis of proteolytic enzymes and other factors that contribute to cartilage matrix damage and cause the death of these cells. Chondroitin sulfate was also shown to exert anti-inflammatory activity. In addition, it acts on osteoarthritic subchondral bone osteoblasts by modulating the osteoprotegerin/receptor activator of NF-kappaB ligand ratio in favor of reduced bone resorption. It is noteworthy to mention that a head-to-head comparison of the effects of chondroitin sulfate of different origins and levels of purity on human osteoarthritic cartilage revealed the existence of a disparity in effects.
CONCLUSION: The positive effects of chondroitin sulfate on the pathophysiology of osteoarthritis are possibly due to its contribution to a proper balance between anabolism/catabolism in the articular tissues. Copyright 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399897     DOI: 10.1016/j.joca.2010.01.015

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  20 in total

Review 1.  Non-surgical management of early knee osteoarthritis.

Authors:  Elizaveta Kon; Giuseppe Filardo; Matej Drobnic; Henning Madry; Mislav Jelic; Niek van Dijk; Stefano Della Villa
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-10-25       Impact factor: 4.342

2.  LC-MS(n) analysis of isomeric chondroitin sulfate oligosaccharides using a chemical derivatization strategy.

Authors:  Rongrong Huang; Vitor H Pomin; Joshua S Sharp
Journal:  J Am Soc Mass Spectrom       Date:  2011-06-23       Impact factor: 3.109

3.  Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI.

Authors:  J-J Railhac; M Zaim; A-S Saurel; J Vial; B Fournie
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

Review 4.  Natural Products for Promoting Joint Health and Managing Osteoarthritis.

Authors:  Yves Henrotin; Ali Mobasheri
Journal:  Curr Rheumatol Rep       Date:  2018-09-19       Impact factor: 4.592

Review 5.  Anti-inflammatory strategies in cartilage repair.

Authors:  Ying Zhang; Tyler Pizzute; Ming Pei
Journal:  Tissue Eng Part B Rev       Date:  2014-06-23       Impact factor: 6.389

6.  Role of proteoglycans on the biochemical and biomechanical properties of dentin organic matrix.

Authors:  Cristina de Mattos Pimenta Vidal; Ariene Arcas Leme-Kraus; Momina Rahman; Ana Paula Farina; Ana K Bedran-Russo
Journal:  Arch Oral Biol       Date:  2017-06-16       Impact factor: 2.633

7.  Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate.

Authors:  Cécile Lambert; Marianne Mathy-Hartert; Jean-Emile Dubuc; Eulàlia Montell; Josep Vergés; Carine Munaut; Agnès Noël; Yves Henrotin
Journal:  Arthritis Res Ther       Date:  2012-03-12       Impact factor: 5.156

8.  Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

Authors:  Lukas Martin Wildi; Jean-Pierre Raynauld; Johanne Martel-Pelletier; André Beaulieu; Louis Bessette; Frédéric Morin; François Abram; Marc Dorais; Jean-Pierre Pelletier
Journal:  Ann Rheum Dis       Date:  2011-03-01       Impact factor: 19.103

9.  Chitosan hydrogels for chondroitin sulphate controlled release: an analytical characterization.

Authors:  Annalisa Bianchera; Enrico Salomi; Matteo Pezzanera; Elisabeth Ruwet; Ruggero Bettini; Lisa Elviri
Journal:  J Anal Methods Chem       Date:  2014-12-31       Impact factor: 2.193

10.  Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties.

Authors:  Valentina Calamia; Lucía Lourido; Patricia Fernández-Puente; Jesús Mateos; Beatriz Rocha; Eulalia Montell; Josep Vergés; Cristina Ruiz-Romero; Francisco J Blanco
Journal:  Arthritis Res Ther       Date:  2012-10-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.